- Report
- May 2024
- 200 Pages
Global
From €3772EUR$4,150USD£3,203GBP
- Report
- November 2024
- 203 Pages
Global
From €4045EUR$4,450USD£3,435GBP
- Report
- April 2025
- 60 Pages
Global
From €1363EUR$1,500USD£1,158GBP
- Report
- May 2024
- 170 Pages
Global
From €2272EUR$2,500USD£1,930GBP
- Report
- April 2025
- 331 Pages
Global
From €5317EUR$5,850USD£4,515GBP
- Report
- April 2025
- 185 Pages
Global
From €4090EUR$4,500USD£3,473GBP
- Report
- April 2025
- 185 Pages
Global
From €4090EUR$4,500USD£3,473GBP
- Report
- April 2025
- 185 Pages
Global
From €4090EUR$4,500USD£3,473GBP
- Report
- April 2025
- 185 Pages
Global
From €4090EUR$4,500USD£3,473GBP
- Report
- April 2025
- 185 Pages
Global
From €4090EUR$4,500USD£3,473GBP
- Report
- February 2025
- 183 Pages
Global
From €4090EUR$4,500USD£3,473GBP
- Report
- February 2025
- 185 Pages
Global
From €4090EUR$4,500USD£3,473GBP
- Report
- February 2025
- 182 Pages
Global
From €4090EUR$4,500USD£3,473GBP
- Report
- January 2025
- 183 Pages
Global
From €4090EUR$4,500USD£3,473GBP
- Report
- May 2024
- 185 Pages
Global
From €4090EUR$4,500USD£3,473GBP
- Report
- May 2024
- 181 Pages
Global
From €4090EUR$4,500USD£3,473GBP
- Report
- May 2024
- 181 Pages
Global
From €4090EUR$4,500USD£3,473GBP
- Report
- May 2024
- 187 Pages
Global
From €4090EUR$4,500USD£3,473GBP
- Report
- May 2024
- 182 Pages
Global
From €4090EUR$4,500USD£3,473GBP
- Report
- July 2024
- 105 Pages
Global
From €4317EUR$4,750USD£3,666GBP

The Antimicrobial Resistance (AMR) market is a subset of the healthcare services industry that focuses on the development of treatments and strategies to combat the growing threat of drug-resistant bacteria. AMR is a major public health concern, as it can lead to increased morbidity and mortality, as well as higher healthcare costs. To address this issue, the market is focused on developing new antibiotics, diagnostics, and vaccines, as well as strategies to reduce the spread of drug-resistant bacteria. Additionally, the market is focused on improving the stewardship of existing antibiotics, as well as developing new strategies to reduce the emergence of drug-resistant bacteria.
Some companies in the AMR market include Merck & Co., Pfizer, GlaxoSmithKline, Sanofi, Johnson & Johnson, Novartis, and AstraZeneca. Show Less Read more